EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity

Natticha Sumneang iD, Pongpan Tanajak iD, Thura Tun Oo iD

Molecules · 24.05.2023 · 28 (11) · 4294

DOI: 10.3390/molecules28114294 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 24.05.2023. Verfasst von Natticha Sumneang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand. Hauptthemen laut MEDLINE: Cardiotoxicity, Toll-Like Receptor 4. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (Dox) is one of the most frequently used chemotherapeutic drugs in a variety of cancers, but Dox-induced cardiotoxicity diminishes its therapeutic efficacy. The underlying mechanisms of Dox-induced cardiotoxicity are still not fully understood. More significantly, there are no established therapeutic guidelines for Dox-induced cardiotoxicity. To date, Dox-induced cardiac inflammation is widely considered as one of the underlying mechanisms involved in Dox-induced cardiotoxicity. The Toll-like receptor 4 (TLR4) signaling pathway plays a key role in Dox-induced cardiac inflammation, and growing evidence reports that TLR4-induced cardiac inflammation is strongly linked to Dox-induced cardiotoxicity. In this review, we outline and address all the available evidence demonstrating the involvement of the TLR4 signaling pathway in different models of Dox-induced cardiotoxicity. This review also discusses the effect of the TLR4 signaling pathway on Dox-induced cardiotoxicity. Understanding the role of the TLR4 signaling pathway in Dox-induced cardiac inflammation might be beneficial for developing a potential therapeutic strategy for Dox-induced cardiotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiotoxicityToll-Like Receptor 4HumansDoxorubicinSignal TransductionInflammationMyocytes, CardiacOxidative StressApoptosis

Stichwörter der Autor:innen

Toll-like receptor 4cardiotoxicitydoxorubicinheart

Substanzen

Toll-Like Receptor 4Doxorubicin

Autor:innen und Institutionen

  • Department of Medical Science, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand.
  • Research Center in Tropical Pathobiology, Walailak University, Nakhon Si Thammarat 80160, Thailand.
  • Department of Physical Therapy, Rehabilitation Center, Apinop Wetchakam Hospital, Kaeng-Khoi District, Saraburi 18110, Thailand.
  • Department of Biomedical Sciences, University of Illinois at Chicago, College of Medicine Rockford, Rockford, IL 61107, USA.

ORCID-Profile: Natticha Sumneang, Pongpan Tanajak, Thura Tun Oo

Zitieren

APA

Sumneang, N., Tanajak, P., & Oo, T. T. (2023). Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity. Molecules, 28(11), 4294. https://doi.org/10.3390/molecules28114294

Vancouver

Sumneang N, Tanajak P, Oo TT. Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity. Molecules. 2023;28(11):4294. doi:10.3390/molecules28114294

BibTeX
@article{Sumneang2023,
  author = {Sumneang, Natticha and Tanajak, Pongpan and Oo, Thura Tun},
  title = {Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {11},
  pages = {4294},
  doi = {10.3390/molecules28114294}
}
Kostenlos starten →